---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-008631"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2026-01-09T23:59:59+00:00"
generated_at: "2026-05-16T11:08:15.940027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M

## Summary
- Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.
- Full-year 2025 net revenue approximately $154.9M (preliminary, unaudited).
- ZYNRELEF net revenue $12.5M in Q4, up ~35% vs Q3 2025, largest product growth.
- APONVIE net revenue $3.8M, CINVANTI $22.9M, SUSTOL $1.3M in Q4 2025.
- CEO Craig Collard cites continued progress across all aspects of business.

## SEC filing metadata
- accession: 0001193125-26-008631
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2026-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/0001193125-26-008631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/hrtx-20260109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-008631
- JSON: https://secwatch.observer/filing/0001193125-26-008631.json
- Plain text: https://secwatch.observer/filing/0001193125-26-008631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.